Research being done on a new eye drop for age-related macular degeneration. It is currently being tested on primates at this time.- MDA
Regorafenib Eye Drops Show Promise in Primate AMD Model
by: Marlene Busko
Topical eye drops of regorafenib (Bayer HealthCare), a multikinase inhibitor targeting vascular endothelial growth factor 2, were safe and effective when given to monkeys that had laser-induced choroidal neovascularization, according to a new study presented in a poster May 4 at the Association for Research in Vision and Ophthalmology 2015 Annual Meeting.
Because existing treatments require intravitreal injections given by physicians, “potentially, regorafenib eye drops offer an innovative, self-administered, noninvasive treatment option for [wet age-related macular degeneration (AMD)],” Dr Michael K. Bötger, from Bayer HealthCare, Wuppertal, Germany, and colleagues conclude.
However, these are early days. “The project is in early development phase,” Dr Kerstin Crusius, head of Global Science and Healthcare Communication, Bayer HealthCare Pharmaceuticals, Berlin, Germany, cautioned Medscape Medical News. Looking into the future, “if everything goes well and once approved, regorafenib eye drops…could become a valuable extension to the current treatment options for wet AMD,” he said. The company had positive results in a phase 1 clinical trial in healthy male volunteers, and a phase 2 clinical trial was initiated in August 2014.
Asked to comment on the abstract, Sunir J. Garg, MD, from the Retina Service of Wills Eye Hospital and associate professor of Ophthalmology at Thomas Jefferson University, Philadelphia, Pennsylvania, said, “[I]t’s a tremendously exciting time for the treatment of wet AMD.” Just a few years ago, there were no treatments for this eye disease. Now ranizumab (Lucentis, Genentech, Novartis) and aflibercept (Eylea,Regeneron, Bayer HealthCare) have been approved by the US Food and Drug Administration (FDA), and bevacizumab (Avastin, Genentech, Roche) is used off-label. “Our hope [for the future] is to get patients better results with greater ease of administration,” he said………
Read more: http://www.medscape.com/viewarticle/844731